Application to the Ministry of Health in Japan for Ravicti® (Glycerol Phenylbutyrate) submitted
Stockholm, December 27, 2024 – Immedica is pleased to announce that its partner OrphanPacific, Inc has submitted an application to the Ministry of Health, Labour and Welfare in Japan for the approval of Ravicti® (glycerol phenylbutyrate) for the treatment of Urea Cycle Disorders (UCD). The submission follows the approval of the orphan drug designation of Ravicti on December 25. "This submission marks a significant step toward bringing this important treatment addition to patients with UCD in Japan. We are pleased to see this progress together with our partner OrphanPacific, as we